Alemtuzumab in clinical practice: A British Columbia experience

References

• Ravandi F, O'Brien S. Alemtuzumab. Expert Rev Anticancer Ther 2005; 5: 39–51
   PubMed Web of Science ®Google Scholar
• Moreton P, Hillmen P. Alemtuzumab therapy in B-cell lymphoproliferative disorders. Semin Oncol 2003; 30: 493–501
   PubMed Web of Science ®Google Scholar
• Dearden C. The role of alemtuzumab in the management of T-cell malignancies. Semin Oncol 2006; 33: S44–S52
   PubMed Web of Science ®Google Scholar
• Giralt S. The role of alemtuzumab in nonmyeloablative hematopoietic transplantation. Semin Oncol 2006; 33: S36–S43
   PubMed Web of Science ®Google Scholar
• Osterborg A, Fassas A S, Anagnostopoulos A, Dyer M J, Catovsky D, Mellstedt H. Humanized CD52 monoclonal antibody Campath-1H as first-line treatment in chronic lymphocytic leukaemia. Br J Haematol 1996; 93: 151–153
   PubMed Web of Science ®Google Scholar
• Lundin J, Kimby E, Bjorkholm M, Broliden P A, Celsing F, Hjalmar V, et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768–773
   PubMed Web of Science ®Google Scholar
• Osterborg A, Dyer M J, Bunjes D, Pangalis G A, Bastion Y, Catovsky D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol 1997; 15: 1567–1574
   PubMed Web of Science ®Google Scholar
• Rai K R, Freter C E, Mercier R J, Cooper M R, Mitchell B S, Stadtmauer E A, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002; 20: 3891–3897
   PubMed Web of Science ®Google Scholar
• Keating M J, Flinn I, Jain V, Binet J L, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002; 99: 3554–3561
   PubMed Web of Science ®Google Scholar
• Osterborg A, Karlsson C, Lundin J, Kimby E, Mellstedt H. Strategies in the management of alemtuzumab-related side effects. Semin Oncol 2006; 33: S29–S35
   PubMed Web of Science ®Google Scholar
• Fiegl M, Falkner A, Hopfinger G, Brugger S, Zabernigg A, Bauer F, et al. Routine clinical use of alemtuzumab in patients with heavily pretreated B-cell chronic lymphocytic leukemia: a nation-wide retrospective study in Austria. Cancer 2006; 107: 2408–2416
   PubMed Web of Science ®Google Scholar
• Cheson B D, Bennett J M, Grever M, Kay N, Keating M J, O'Brien S, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996; 87: 4990–4997
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Trotti A, Colevas A D, Setser A, Rusch V, Jaques D, Budach V, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176–181
   PubMed Web of Science ®Google Scholar
• Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50: 163–170
   PubMedGoogle Scholar
• Montserrat E, Moreno C, Esteve J, Urbano-Ispizua A, Gine E, Bosch F. How I treat refractory CLL. Blood 2006; 107: 1276–1283
   PubMed Web of Science ®Google Scholar
• McCune S L, Gockerman J P, Moore J O, Decastro C M, Bass A J, Chao N J, et al. Alemtuzumab in relapsed or refractory chronic lymphocytic leukemia and prolymphocytic leukemia. Leuk Lymphoma 2002; 43: 1007–1011
   PubMed Web of Science ®Google Scholar
• Rai K R, Keating M J, Coutre S, Rizzieri D A, on behalf of the Campath-1H Study Group. Patients with refractory B-CLL and T-PLL treated with alemtuzumab (CamPath) on a compassionate basis. A report on efficacy and safety of CAM 511 trial. Blood 2002; 100: 802a, (abtr 3165)
   Web of Science ®Google Scholar
• Keating M J, O'Brien S, Kontoyiannis D, Plunkett W, Koller C, Beran M, et al. Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia. Leuk Lymphoma 2002; 43: 1755–1762
   PubMed Web of Science ®Google Scholar
• Capalbo S, Delia M, Dargenio M, Liso A, Diomede D, Garofalo L, et al. Mycosis fungoides/Sezary syndrome: a report of three cases treated with Campath-1H as salvage treatment. Med Oncol 2003; 20: 389–396
   PubMed Web of Science ®Google Scholar
• Lundin J, Osterborg A, Brittinger G, Crowther D, Dombret H, Engert A, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol 1998; 16: 3257–3263
   PubMed Web of Science ®Google Scholar
• Lenihan D J, Alencar A J, Yang D, Kurzrock R, Keating M J, Duvic M. Cardiac toxicity of alemtuzumab in patients with mycosis fungoides/Sezary syndrome. Blood 2004; 104: 655–658
   PubMed Web of Science ®Google Scholar
• Lundin J, Kennedy B, Dearden C, Dyer M J, Osterborg A. No cardiac toxicity associated with alemtuzumab therapy for mycosis fungoides/Sezary syndrome. Blood 2005; 105: 4148–4149
   PubMed Web of Science ®Google Scholar
• Ferrajoli A, O'Brien S M, Cortes J E, Giles F J, Thomas D A, Faderl S, et al. Phase II study of alemtuzumab in chronic lymphoproliferative disorders. Cancer 2003; 98: 773–778
   PubMed Web of Science ®Google Scholar